Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Coiffier B, et al. Among authors: theocharous p. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Zinzani PL, Khuageva NK, Wang H, Garicochea B, Walewski J, Van Hoof A, Soubeyran P, Caballero D, Buckstein R, Esseltine DL, Theocharous P, Enny C, Zhu E, Elsayed YA, Coiffier B. Zinzani PL, et al. Among authors: theocharous p. J Hematol Oncol. 2012 Oct 22;5:67. doi: 10.1186/1756-8722-5-67. J Hematol Oncol. 2012. PMID: 23088650 Free PMC article. Clinical Trial.
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA, van de Velde H, Schaffer ME, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Romejko-Jarosinska J, de Vos S, Crump M, Shpilberg O, Zinzani PL, Cakana A, Esseltine DL, Mulligan G, Ricci D. Coiffier B, et al. Among authors: theocharous p. Clin Cancer Res. 2013 May 1;19(9):2551-61. doi: 10.1158/1078-0432.CCR-12-3069. Epub 2013 Apr 2. Clin Cancer Res. 2013. PMID: 23549871
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B. Pettengell R, et al. Among authors: theocharous p. Br J Haematol. 2016 Sep;174(5):692-9. doi: 10.1111/bjh.14101. Epub 2016 Apr 26. Br J Haematol. 2016. PMID: 27118109 Free PMC article. Clinical Trial.
A novel murine model of allogeneic vaccination against prostate cancer.
Labarthe MC, Theocharous P, Russell N, Todryk S, Bangma C, Thraves P, Dalgleish AG, Whelan MA. Labarthe MC, et al. Among authors: theocharous p. Cancer Immunol Immunother. 2008 Apr;57(4):453-65. doi: 10.1007/s00262-007-0384-2. Epub 2007 Sep 6. Cancer Immunol Immunother. 2008. PMID: 17805533 Free PMC article.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D, Richards R, Faber EA, Deol A, Hunter BD, Weber E, DiFilippo H, Henderson-Clark T, Meaux L, Crivera C, Riccobono C, Garrett A, Jackson CC, Fowler J, Theocharous P, Stewart R, Lorden AL, Porter DL, Berger A. Hoda D, et al. Among authors: theocharous p. Future Oncol. 2022 Jun;18(19):2415-2431. doi: 10.2217/fon-2022-0162. Epub 2022 May 18. Future Oncol. 2022. PMID: 35583358
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.
Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K. Borgen E, et al. Among authors: theocharous p. Cytotherapy. 1999;1(5):377-88. doi: 10.1080/0032472031000141283. Cytotherapy. 1999. PMID: 20426539
11 results